ERBC

ERBC Group is a France-based, full-service preclinical CRO with a significant European footprint, operating since 1972 in Italy and 1973 in France. It offers a broad portfolio of services including safety assessment, laboratory sciences, clinical central lab, and specialized models like non-human primates (NHP) and patient-derived xenografts (PDX). The company positions itself as a scientific partner that advises on regulatory strategy and employs New Alternative Methods (NAMs) to de-risk product development for a diverse client base across multiple industries. With a strong track record of timely delivery and extensive study experience, ERBC is a established player in the preclinical services market.

Integrated preclinical CRO platform offering comprehensive in vivo (rodent, non-rodent, NHP, PDX models) and in vitro services, New Alternative Methods (NAM) for reduced animal testing, full analytical laboratory sciences (bioanalysis, histopathology, etc.), and regulatory consultancy.

ERBC competes in a fragmented global preclinical CRO market against large players like Charles River Laboratories, Labcorp, and Eurofins, as well as numerous regional and niche specialists. It differentiates through its deep European roots, specific expertise in NHP and PDX models, integrated service offering, and a strong focus on alternative methods (NAM).